Henan Taloph Pharmaceutical Stock Co.,Ltd
Shanghai Stock ExchangeTotal Valuation
Henan Taloph Pharmaceutical Stock Co.,Ltd carries a market capitalization of 4.46B, placing it among publicly traded companies globally. Its enterprise value stands at 4.76B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.46B |
| Enterprise Value | 4.76B |
Share Statistics
Henan Taloph Pharmaceutical Stock Co.,Ltd currently has 573.89M shares outstanding.
| Shares Outstanding | 573.89M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Henan Taloph Pharmaceutical Stock Co.,Ltd trades at a trailing price-to-earnings ratio of 71.03. The price-to-sales ratio is 2.88, and the price-to-book ratio stands at 4.25.
| PE Ratio | 71.03 |
| PS Ratio | 2.88 |
| PB Ratio | 4.25 |
| P/TBV Ratio | 3.01 |
| P/FCF Ratio | 271.98 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Henan Taloph Pharmaceutical Stock Co.,Ltd trades at an EV/EBITDA multiple of 33.96 and an EV/FCF ratio of 77.47. The EV/Sales ratio of 3.50 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 33.96 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.50 |
| EV / EBITDA | 33.96 |
| EV / EBIT | 33.96 |
| EV / FCF | 77.47 |
Financial Position
Henan Taloph Pharmaceutical Stock Co.,Ltd maintains a current ratio of 1.26, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 58.58, indicating elevated leverage, while an interest coverage ratio of 2.55 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.26 |
| Quick Ratio | 0.10 |
| Debt / Equity | 58.58 |
| Debt / EBITDA | 6.95 |
| Interest Coverage | 2.55 |
Financial Efficiency
Henan Taloph Pharmaceutical Stock Co.,Ltd posts a return on equity of 6.23 and a return on invested capital of 4.51.
| Return on Equity (ROE) | 6.23 |
| Return on Assets (ROA) | 1.52 |
| Return on Invested Capital (ROIC) | 4.51 |
| Return on Capital Employed (ROCE) | 5.11 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.33 |
Taxes
Over the trailing twelve months, Henan Taloph Pharmaceutical Stock Co.,Ltd has paid 9.74M in income taxes, reflecting an effective tax rate of 14.44.
| Income Tax | 9.74M |
| Effective Tax Rate | 14.44 |
Stock Price Statistics
Henan Taloph Pharmaceutical Stock Co.,Ltd's stock has gained approximately 36.31757% over the past 52 weeks. The 50-day moving average sits at 7.57, while the 200-day moving average is 7.14.
| Beta (5Y) | N/A |
| 52-Week Price Change | 36.31757% |
| 50-Day Moving Average | 7.57 |
| 200-Day Moving Average | 7.14 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Henan Taloph Pharmaceutical Stock Co.,Ltd generated 1.36B in revenue and converted that into 55.09M in net income, yielding earnings per share of 0.10. EBITDA reached 140.29M, while operating income came in at 140.29M.
| Revenue | 1.36B |
| Gross Profit | 397.33M |
| Operating Income | 140.29M |
| Pretax Income | 67.42M |
| Net Income | 55.09M |
| EBITDA | 140.29M |
| EBIT | 140.29M |
| Earnings Per Share (EPS) | 0.10 |
Balance Sheet
Henan Taloph Pharmaceutical Stock Co.,Ltd holds 181.53M in cash and equivalents against 974.84M in total debt, resulting in a net debt position of 649.81M. Total book value stands at 920.02M, with working capital of 450.21M providing operational flexibility.
| Cash & Cash Equivalents | 181.53M |
| Total Debt | 974.84M |
| Net Debt | 649.81M |
| Equity (Book Value) | 920.02M |
| Book Value Per Share | 1.66 |
| Working Capital | 450.21M |
Cash Flow
After subtracting -14.39M in capital expenditures, free cash flow totaled -14.39M - equivalent to -0.03 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -14.39M |
| Free Cash Flow | -14.39M |
| FCF Per Share | -0.03 |
Margins
Henan Taloph Pharmaceutical Stock Co.,Ltd operates with a gross margin of 29.21, reflecting its pricing power and cost economics. The operating margin of 10.31 and net profit margin of 4.05 provide insight into operational efficiency.
| Gross Margin | 29.21 |
| Operating Margin | 10.31 |
| Pretax Margin | 4.96 |
| Profit Margin | 4.05 |
| EBITDA Margin | 10.31 |
Dividends & Yields
The company's payout ratio of 79.64 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.09 |
| Dividend Yield | N/A |
| Payout Ratio | 79.64 |
| Shareholder Yield | 4.20 |
| FCF Yield | 0.37 |
Stock Splits
Henan Taloph Pharmaceutical Stock Co.,Ltd's most recent stock split took place on May 12, 2010 with a 10:13 split ratio.
| Last Split Date | 5/12/2010 |
| Split Ratio | 10:13 |
Scores
Henan Taloph Pharmaceutical Stock Co.,Ltd posts an Altman Z-Score of 2.03, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.03 |